RGNX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Regenxbio Inc (RGNX) is not a good buy at the moment for a beginner investor with a long-term strategy. The stock faces significant negative catalysts, including regulatory challenges, class action lawsuits, and competitive pressures. Despite some positive financial growth and analyst optimism for certain programs, the overall sentiment and technical indicators do not support a strong buy decision.
The stock is in a bearish trend with moving averages showing SMA_200 > SMA_20 > SMA_5. RSI is neutral at 45.112, and MACD is slightly positive at 0.0277 but not strongly bullish. The pre-market price of $8.2 is below the pivot level of $8.4, indicating potential further downside. Key support levels are at $7.881 and $7.56.
Revenue increased by 43.00% YoY in Q4 2025, and gross margin improved to 80.46%. Analysts maintain Buy ratings with expectations for positive developments in RGX-202 and ABBV-RGX-314 programs.
FDA clinical hold on RGX-111 and RGX-121 due to safety concerns, class action lawsuits for alleged securities fraud, and competitive pressure from Denali Therapeutics' FDA approval for a similar treatment. Pre-market price drop of -0.73% and bearish technical indicators further weigh on sentiment.
In Q4 2025, revenue grew by 43.00% YoY to $30.34M, net income loss improved by 31.19% YoY to -$67.15M, and EPS increased by 28.71% YoY to -1.3. Gross margin rose to 80.46%, reflecting operational improvements.
Analysts have lowered price targets recently but maintain Buy or Overweight ratings. Price targets range from $12 to $50, with optimism focused on RGX-202 and ABBV-RGX-314 programs. However, regulatory setbacks and safety concerns have led to significant downward revisions.
